In global trust barometers, scientists have long featured among the professions most trusted by the public, but pharmaceutical companies remain the least trusted. This is an interesting dichotomy, given that most pharmaceutical employees are scientists. Public trust has been an issue for the pharmaceutical industry for many years, driven principally by a few high-profile examples […]
Every flu season is unpredictable. And while flu activity in the 2020–2021 season appears to be low so far, there may be a rise in influenza cases in the coming months at the same time the US is seeing an unprecedented number of COVID-19 cases. With emergency rooms and hospitals strained to capacity due to […]
We all want clear messaging on preventing the spread of COVID-19, whether it relates to vaccines, face masks, social distancing or any other guidance. That reflects our mantra within the healthcare communications industry: provide clear, concise and consistent messages that audiences understand. But science, by its nature, is associated with a level of uncertainty. And […]
The current paradigm to strive to diagnose and treat diseases early and effectively remains unquestionable. However, COVID-19 has challenged this central dogma and left us with an unparalleled growing global healthcare crisis. Reports are clear that the pandemic is creating numerous ripple effects for patients who are facing delays to both the diagnosis and treatment […]
The spread of COVID-19 has affected every industry, every facet of life. But its impact on healthcare providers is significantly higher than most and continues to create a ripple effect of significant burdens. Not only are healthcare workers experiencing grave challenges at work, but their concerns and worries extend home to their family members. Heathcare […]
Many companies, particularly new entrants into the U.S. pharma arena, are facing some level of disruption or impact on their projected timelines for seeking FDA licensure, gathering data from trials for filing, conducting health economics analyses needed to demonstrate improved outcomes, or conducting real-world evidence studies that can help inform medical societies’ deliberations on clinical […]
The availability of data, experts for authoring abstracts, posters and oral presentations, and congress activities themselves have all been affected by the pandemic.
While initial impressions may be that the COVID-19 pandemic is creating a barrier for medical education initiatives, this is not necessarily the case across the board.
Many companies are facing challenging decisions on whether to proceed with clinical trials in the coming months as countries experience varying degrees of lockdown.
Medical congresses – crucial for the presentation of trial data, scientific exchange and the opportunity to engage with medical professionals, patient advocates, media and analysts – have been cancelled, postponed or are moving to virtual/part virtual.